T-DXd is indicated for the treatment of HER2-positive advanced breast cancer (aBC), previously treated with an anti-HER2-based regimen in the metastatic/neoadjuvant/adjuvant setting, if disease recurrence occurs during or within 6 months of completing therapy. This evidence concerns the gene ERBB2 and aneurysmal bone cyst.